5AM Venture Management LLC Sells 454,055 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

5AM Venture Management LLC trimmed its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 35.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 830,945 shares of the company's stock after selling 454,055 shares during the period. Centessa Pharmaceuticals comprises approximately 3.3% of 5AM Venture Management LLC's investment portfolio, making the stock its 12th biggest position. 5AM Venture Management LLC owned approximately 0.63% of Centessa Pharmaceuticals worth $13,918,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in CNTA. Schonfeld Strategic Advisors LLC acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth $6,117,000. Foresite Capital Management VI LLC purchased a new stake in Centessa Pharmaceuticals during the fourth quarter valued at about $20,994,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Centessa Pharmaceuticals by 19.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 317,329 shares of the company's stock worth $5,315,000 after buying an additional 52,360 shares during the period. Boothbay Fund Management LLC purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth approximately $702,000. Finally, Lord Abbett & CO. LLC raised its holdings in shares of Centessa Pharmaceuticals by 63.6% during the fourth quarter. Lord Abbett & CO. LLC now owns 440,495 shares of the company's stock valued at $7,378,000 after acquiring an additional 171,290 shares during the period. Institutional investors and hedge funds own 82.01% of the company's stock.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $17.17, for a total transaction of $120,190.00. Following the completion of the sale, the insider now owns 225,007 shares of the company's stock, valued at $3,863,370.19. This represents a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the transaction, the chief executive officer now directly owns 331,017 shares in the company, valued at approximately $5,273,100.81. This represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 202,353 shares of company stock valued at $3,286,478 over the last quarter. Insiders own 11.59% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on CNTA shares. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating on the stock. Guggenheim reissued a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective for the company. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $27.71.

Centessa Pharmaceuticals Stock Up 2.0 %

Shares of Centessa Pharmaceuticals stock traded up $0.24 during trading on Wednesday, hitting $12.25. 185,910 shares of the stock traded hands, compared to its average volume of 617,923. The stock has a market cap of $1.63 billion, a P/E ratio of -8.01 and a beta of 1.53. The company has a fifty day moving average price of $14.07 and a two-hundred day moving average price of $15.74. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. Equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.